US20220362451A1 - Apparatus And Method For Contacting Blood With Ozone - Google Patents
Apparatus And Method For Contacting Blood With Ozone Download PDFInfo
- Publication number
- US20220362451A1 US20220362451A1 US17/815,549 US202217815549A US2022362451A1 US 20220362451 A1 US20220362451 A1 US 20220362451A1 US 202217815549 A US202217815549 A US 202217815549A US 2022362451 A1 US2022362451 A1 US 2022362451A1
- Authority
- US
- United States
- Prior art keywords
- blood
- ozone
- flow
- ozonation
- containing gas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 226
- 239000008280 blood Substances 0.000 title claims abstract description 226
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 title claims abstract description 150
- 238000000034 method Methods 0.000 title claims abstract description 63
- 230000017531 blood circulation Effects 0.000 claims abstract description 21
- 238000006385 ozonation reaction Methods 0.000 claims description 88
- 239000007789 gas Substances 0.000 claims description 65
- 238000001816 cooling Methods 0.000 claims description 17
- 238000010792 warming Methods 0.000 claims description 16
- 239000001301 oxygen Substances 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 5
- 238000002617 apheresis Methods 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000005187 foaming Methods 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000004581 coalescence Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 244000005700 microbiome Species 0.000 abstract description 5
- 238000005086 pumping Methods 0.000 description 10
- 238000012545 processing Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000028172 protozoa infectious disease Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0094—Gaseous substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/20—Gaseous substances, e.g. vapours
- A61L2/202—Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/022—Filtration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
- B01F23/20—Mixing gases with liquids
- B01F23/23—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids
- B01F23/231—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids by bubbling
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
- B01F23/20—Mixing gases with liquids
- B01F23/23—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids
- B01F23/231—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids by bubbling
- B01F23/23105—Arrangement or manipulation of the gas bubbling devices
- B01F23/2312—Diffusers
- B01F23/23123—Diffusers consisting of rigid porous or perforated material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
- B01F23/20—Mixing gases with liquids
- B01F23/23—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids
- B01F23/237—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids characterised by the physical or chemical properties of gases or vapours introduced in the liquid media
- B01F23/2376—Mixing gases with liquids by introducing gases into liquid media, e.g. for producing aerated liquids characterised by the physical or chemical properties of gases or vapours introduced in the liquid media characterised by the gas being introduced
- B01F23/23761—Aerating, i.e. introducing oxygen containing gas in liquids
- B01F23/237613—Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/22—Blood or products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3623—Means for actively controlling temperature of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0216—Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3606—General characteristics of the apparatus related to heating or cooling cooled
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F2215/00—Auxiliary or complementary information in relation with mixing
- B01F2215/04—Technical information in relation with mixing
- B01F2215/0413—Numerical information
- B01F2215/0418—Geometrical information
- B01F2215/0431—Numerical size values, e.g. diameter of a hole or conduit, area, volume, length, width, or ratios thereof
Definitions
- the present invention relates to methods and apparatus for treating biological fluids with ozone. More particularly, the invention pertains to methods and apparatus for treating blood with ozone.
- Ozone is a strong oxidizing agent that has been used as a disinfectant. Despite the corrosive and highly reactive nature of ozone, the use of ozone to kill or inactivate certain infectious agents in blood has been explored.
- US 2005/0189302 A1 discloses a method of inactivating viruses in blood by exposing the blood to ozone in a gas-fluid contacting device that maximizes gas-fluid mass transfer.
- the contacting device contains spheres or rods to form a thin film of blood and treatment is preferably performed at ambient temperature.
- WO 2011/162805 A2 discloses methods for inactivating infectious prion proteins in blood by subjecting blood to an ozone/oxygen admixture using a gas-fluid contacting device similar to that disclosed in US 2005/0189302 A1.
- WO 93/15779 A1 discloses a method of increasing the nitric oxide concentration in the blood by contacting a sample of blood with ozone gas and ultraviolet radiation.
- the treated sample of blood is administered to a patient to treat a variety of conditions including bacterial, fungal, viral, and protozoal infection.
- the blood sample is most preferably a volume of 1 to 50 mL and is most preferably treated at a temperature of 42.5° C. for approximately 3 minutes.
- U.S. Pat. No. 6,027,688 discloses a method for inactivating viruses, bacteria, fungi and protozoa in blood by contacting a flow of blood with counter-flow of an ozone-oxygen mixture for about 16 seconds using a gas-liquid contact apparatus.
- Treating milk and other liquid foodstuffs with ozone to kill bacteria is known.
- WO 2008/066470 discloses a method for inhibiting bacterial growth in milk by exposing the milk to a finely divided gas stream containing ozone at ambient temperature.
- the method of ozonation disclosed in WO2008/066470 can be improved regarding efficiency.
- the temperature of the liquid ozonized is ambient temperature.
- the ambient temperature may be an ambient storage and transport temperature, but the temperature at the ozonation location is not disclosed as needing temperature control in the method disclosed in WO2008/066470.
- ozone has been used for killing microbes in large volumes of dairy products, such methods would destroy blood cells and inactivate enzymes and other proteins in the blood.
- Embodiments of the present invention preferably seek to mitigate, alleviate or eliminate one or more deficiencies, disadvantages or issues in the art, such as the above-identified, singly or in any combination by providing an apparatus for contacting blood with ozone, an ozonation system comprising the apparatus, and a method for contacting blood with ozone, according to the appended patent claims. While the invention is described with respect to the ozonation of blood and contacting blood with ozone, the invention is applicable to the ozonation of other biological fluids such as blood plasma, blood cell suspensions, and suspensions of other cell types.
- an ozonation apparatus for contacting blood with ozone.
- the apparatus comprises an ozone injector adapted to inject microbubbles of ozone containing gas into a flow of blood in an ozonation zone of an ozone contacting chamber, or ozonation chamber.
- the apparatus may optionally comprise means for cooling blood entering the ozonation chamber and/or means for warming blood exiting the ozonation chamber.
- an apparatus for contacting blood with ozone gas has an ozonation chamber, a blood flow inlet, and a blood flow outlet.
- the ozonation chamber includes an ozone injector 3 configured for connection to a source of ozone containing gas and to inject bubbles of ozone containing gas into a flow of blood through the ozonation chamber.
- the flow of blood is directed vertically upwards through the blood ozonation chamber during injection.
- Suitable conduits are provided for directing the flow in relation to gravity so that the flow is vertically upwards at injection of ozone into the blood.
- the ozonation chamber and the ozone injector are configured such that the vertically upwards flow of blood through the blood ozonation chamber entrains bubbles of ozone containing gas into said flow of blood for said ozonation.
- the gas bubbles become dissolved in the blood when entrained therein.
- a blood ozonation system comprising the ozonation apparatus, a source of ozone connected to the ozone injector, conduits for receiving blood into and delivering blood from the apparatus, and pumping means for pumping blood through the system.
- the system optionally comprises cooling means for cooling the blood before entering the ozonation apparatus and/or warming means for warming ozonated blood leaving the ozonation apparatus.
- a method for contacting blood with ozone involves contacting blood with micro-sized bubbles of a gas containing ozone.
- the blood is at a temperature of less than 12° C. when contacted with the microbubbles, the microbubbles have a mean diameter of less than 5 ⁇ m.
- a method for contacting blood with ozone involves receiving blood, cooling the blood to a temperature of less than 12° C., contacting the chilled blood with microbubbles of a gas containing ozone, optionally warming the blood to a warmed temperature, and delivering the blood to a storage container or storage vessel.
- a method for treating a patient suffering from microbial infection involves receiving blood from the patient, cooling the blood to a temperature of less than 12° C., contacting the chilled blood with microbubbles of a gas containing ozone, warming the blood, and returning the blood to the patient.
- the method is advantageously performed using the system or apparatus of the disclosure.
- microorganism as used herein is synonymous with “microbe” and means any microorganism including bacteria, virus, fungi or yeast, and including spores or dormant forms of such a microorganisms.
- FIG. 1 is a schematic of a first embodiment of an ozonation system comprising an apparatus for contacting blood with ozone.
- FIG. 2 is a schematic of a second embodiment of an ozonation system comprising an apparatus for contacting blood with ozone.
- FIG. 3 is a flow chart of method steps for a method for contacting blood with ozone.
- FIG. 1 A first embodiment of an ozonation system according to the invention is shown in FIG. 1 .
- the apparatus comprises an ozonation apparatus 1 comprising an ozonation chamber 2 comprising an inlet 2 a and an outlet 2 b, and an ozone injector 3 .
- the ozone injector 3 is configured to be connected to a source of ozone gas 4 .
- the source of ozone gas may be an ozone generator that produces ozone from oxygen that may produce a gas mixture that contains ozone and oxygen at a certain ratio.
- Alternative gaseous ozone sources may be provided as known to the skilled person.
- the ratio of ozone to oxygen in the gas mixture may for example range from 5% to 20% ozone and from 95% to 80% oxygen. Preferable values of an ozone to oxygen ratios are 5/95, 10/90, 15/85 and 20/80.
- the ozone injector may be made from porous material, for example, from sintered stainless steel. Alternatively or in addition, it may be made from sintered ceramic. Alternatively, or in addition other gas injectors may be provided to provide ozone gas to enrich a flow of blood to be ozonized. Other gas injectors may be nozzle based.
- the porous material has in examples a uniform mean pore size of less than 5 ⁇ m in diameter, such as 4 ⁇ m, 3 ⁇ m, 2 ⁇ m, 1 ⁇ m, 0.5 ⁇ m, or 0.2 ⁇ m. The pore size is preferably between about 0.2 ⁇ m and about 2.0 ⁇ m.
- the ozone gas injector 3 may further comprises a flow meter, pressure valve, pressure sensor, and/or controlling element to facilitate monitoring and/or control the pressure and/or flow rate of gas being injected.
- FIG. 1 shows an ozonation apparatus 1 comprising a porous ozone injector 3 inside an ozonation chamber 2 .
- the ozone injector is cylindrical in the example.
- the ozonation chamber is configured to guide a flow of blood around the porous microbubble releasing surface of the ozone injector 3 .
- the ozone injector is cylindrical.
- the cylindrical ozone injector 3 is arranged co-axially in the cylindrical ozonation chamber for advantageous ozonation efficiency.
- a gap exists between the inner wall of the ozonation chamber 2 and the porous bubble releasing surface of the ozone injector 3 .
- the bubble as preferably microbubbles as elucidated herein.
- the flow of blood over the microbubble releasing surface is preferably a laminar flow to minimize turbulence in the blood flow.
- the blood flow is preferably directed vertically upwards so that gas bubbles entrain in the flow of blood.
- gas bubbles are entrained upwardly.
- the gas bubbles are also provided to the entire flow of blood, independent of gravity.
- the gas bubbles are for instance evenly provided around a cylindrical ozone injector. In this manner, portions of blood that are not enriched with gas comprising ozone are avoided.
- the vertical direction provides thus advantageous (short) time of gas comprising ozone with the flow of blood until the gas is dissolved in the blood. This is important as for instance remaining gas bubbles returned to a patient have to avoided.
- foaming of the blood flow is advantageously reduced or avoided by the vertical arrangement of the blood flow.
- the shape of the ozone injector 3 need not be cylindrical and not all surfaces of the ozone injector need to be in contact with blood.
- One alternative configuration is shown in FIG. 2 .
- the ozone injector 3 is arranged in the ozonation chamber 2 such that blood flow is restricted to pass through ozonation chamber 2 within a maximum distance (d) of a porous surface of the ozone injector 3 from which microbubbles are released.
- the maximum distance (d) is preferably less than about 2 mm, such as 1.5 mm, 1.0 mm, 0.75 mm, 0.5 mm, 0.25 mm, or 0.1 mm or any distance within this range.
- the ozonation chamber 2 and ozone injector 3 are designed to provide an ozonation zone 5 in which micrometer sized bubbles of ozone containing gas mix with and dissolve in a flow of blood.
- an ozonation region 5 When blood and ozone containing gas are flowing through the ozonation chamber 1 , an ozonation region 5 , indicated as the region between the horizontal dashed lines in FIG. 1 , exists in which microbubbles are entrained in the blood flow. The bubbles are dissolved in the blood along the entrainment path in the blood flow.
- the duration of ozone contacting time, or dwell time is determined by a number of factors. These factors include the concentration of ozone in the gas, and the flow rate of the gas. Another factor is the temperature of the blood. The temperature at ozonation is preferably controlled in examples of the disclosure. Moreover, the flow rate of the blood is such a factor. Any or all of these factors may be measured, supervised, or controlled to optimize ozonation. The factors maybe computer controlled by controlling gas pressure and flow from the source of ozone 4 . Alternatively, or in addition, the operation of blood pumping means 10 may be controlled. Optionally blood cooling means 11 are controlled for advantageous blood ozonation.
- a system according to an example of the present disclosure may comprise more than one ozonation apparatus.
- a plurality of ozone apparatus may be arranged in parallel with respect to the flow of blood.
- a single ozone apparatus can comprise a plurality of ozone injectors.
- Each or some of the plurality of ozone injectors may be arranged such that all blood moving through the ozonation chamber passes within the maximum distance (d) of at least one of the ozone injectors.
- the ozonation system shown in FIG. 1 additionally may, as illustrated, comprises blood pumping means 10 .
- the blood pumping means 10 are arranged for pumping blood through the apparatus or system from a blood inlet portion 8 to a blood outlet portion 9 .
- Suitable blood pumping means 10 for pumping blood are known in the art and may comprise, for example, a peristaltic pump, a roller pump, or a centrifugal pump.
- Pumping means 10 may be capable of pumping blood through the system at a suitable flow rate. Suitable flow rates range for example from about 0.1 Liters/hour to about 12 Liters/hour.
- the system may also comprise an ozone source 4 , such as a medical grade ozone generator.
- the ozone generator is fluidly connected to the ozone injector 3 by a gas conduit 6 .
- the gas conduit 6 may comprise a one-way valve 7 to prevent backflow of blood into the ozone generator 6 . Such backflow may occur in case of, for example, a sudden pressure drop in the gas conduit 6 .
- the ozone source 4 is preferably capable of delivering ozone at a constant pressure.
- the ozone source 4 is preferably capable of delivering at least 10% ozone at such a constant pressure.
- the constant pressure of gas is at least 0.1 bar and preferably up to 0.5 bar, 0.75 bar or 1.0 bar at the ozone injector 3 .
- the system may additionally comprise a source of one or more inert gasses that may be mixed with the ozone containing gas before reaching the ozone injector.
- inert gasses include nitrogen and helium.
- the blood contacting portions of the system may preferably be made of any suitable biocompatible materials.
- Such materials include materials typically used to transfer or store blood, such as those used in tubing for transfusions or blood conducting portions of heart and lung machine or apheresis machines.
- the blood entry portion 2 may comprise or be connectable to means for receiving blood from a patient such as a hollow needle for insertion in to a vein.
- blood entry portion 2 may comprise means for receiving blood from a container of blood.
- a container of blood may include a bag or bottle or an extracorporeal blood circulation device such as an apheresis machine, dialysis machine, or heart and lunch machine.
- the ozonation system may comprise blood cooling means 11 positioned upstream of ozonation apparatus inlet 2 a and configured to cool the blood to a chilled temperature of less than 12° C. before the blood enters the ozonation apparatus 1 .
- the blood cooling means 11 may comprise any suitable blood heat exchanger used in the medical arts to cool blood and may be configured for computer control of the temperature of the blood entering the ozonation chamber 2 .
- the blood cooling means 11 is preferably controllable to cool said blood to a temperature of between about 4° C. and about 12° C., to produce chilled blood that is contacted with ozone containing gas in the ozonation chamber 2 .
- cooling is a relative term. If for instance blood entering into the ozonation system has a temperature lower than desired, e.g. lower than between about 4° C. and about 12° C., it maybe provided to actually heat the blood to this preferred temperature range. This may be the case for frozen blood preservatives, e.g. frozen blood plasma. Cooling can be understood a term relative to ambient room temperature. Cooling is also relative physiological body temperature if blood is input to the ozonation system at body temperature from a patient.
- the blood thus has preferably a temperature of less than 12° C. It preferably has a temperature between about 4° C. and about 12° C.
- the chilled blood is then contacted at this temperature with ozone containing gas in the ozonation chamber 2 .
- the ozonation system may comprise blood warming means 12 .
- the blood warming means is preferably positioned downstream the ozonation chamber.
- the blood warming means is for example positioned downstream of the outlet 2 b from the ozonation apparatus 1 .
- the blood warming means is configured to warm ozonated blood to a temperature above the blood temperature in the ozonation chamber 2 .
- the blood warming means 12 may be configured to warm blood to a body temperature of a human or nonhuman animal, e.g. between about 24° C. to about 39° C.
- Blood warming means 12 may additionally or alternatively be configured to adjust the temperature of the blood to a storage temperature. It is understood that warming is a relative term. If for instance blood leaving the ozonation system has a temperature higher than desired to exit the apparatus or system, it maybe provided to actually, potentially further, cool the blood to this desired temperature. This may be the case when it is desired to provide ozonated frozen blood preservatives, e.g. frozen blood plasma, with advantageous storage properties compared to not ozonated blood products.
- ozonated frozen blood preservatives e.g. frozen blood plasma
- Blood warming will in most examples include feeding heat energy to the ozonated blood to increase the temperature thereof.
- Blood warming means 12 may be computer controlled similarly to blood cooling means 11 .
- the system may comprise a blood processing unit 13 comprising means for removing bubbles, preferably downstream the ozone injector.
- the system may comprise a blood processing unit 13 comprising means for removing foam, preferably downstream the ozone injector.
- the system may comprise a blood processing unit 13 comprising means for removing thrombi, preferably downstream the ozone injector. In this manner, undesired bubbles, foam, thrombi, and/or other material may be suitably removed.
- the treatment may be at least partially be done upstream the ozonation chamber.
- the treatment is preferably done downstream (relative blood flow) the ozonation chamber, for instance before the blood can be delivered to a patient or to a blood storage container.
- Blood processing unit 13 may comprise, for example, a filter for removing particles .
- the blood processing unit 13 may comprise a blood reservoir comprising an inlet region separated from an outlet region by a membrane that is permeable for blood, but impermeable for air bubbles.
- a blood processing unit 13 downstream the ozonation chamber may be particularly useful in embodiments of the invention used to ozonate blood that is to be delivered to a patient.
- All or parts of the apparatus and/or system may be combined with and/or controlled by a computerized control system 19 .
- the computerized control system 19 may be electrically coupled to sensors, actuators, valves, and/or switches in the ozonation system.
- the control system 19 may comprise software having code segments configured to control operational parameters of the apparatus.
- Operational parameters include parameters such as blood and gas flow rates and pressures, the concentration of ozone and other gasses in the ozone containing gas, blood temperature in the different portions of the apparatus, and blood flow rates in various portions of the apparatus and/or system conduit based upon sensor data received from pressure, flow, temperature, and/or chemical sensors provided in various portions of the apparatus.
- FIG. 2 shows an example of an ozonation system comprising an alternatively configured ozonation apparatus 1 . Only the top surface of the ozone injector 3 is in contact with blood and injects microbubbles of ozone containing gas into a flow of blood that entrains the injected microbubbles. An ozonation region 5 is located directly above the ozone injector 3 in which the microbubbles completely dissolve in the blood.
- the ozone is also entirely consumed by chemical reactions with the blood within the ozonation region 5 .
- the ozonation chamber 2 is configured such that all of the blood flow passes within a maximum distance (d) from the upper surface of the ozone injector 3 .
- the maximum distance (d) is preferably less than about 2 mm, such as 1.5 mm, 1.0 mm, 0.75 mm, 0.5 mm, 0.25 mm, or 0.1 mm or any distance within this range.
- the diameter of blood flow can be narrowed above the ozone injector 3 such that a flow of blood entrains a flow of microbubbles in an ozonation zone 5 above the injector.
- the maximum distance from the surface of the ozone injector 3 may be greater than in other embodiments.
- the diameter of the flow in the ozonation zone 5 is preferably less than about 2 mm, such as 1.5 mm, 1.0 mm, 0.75 mm, 0.5 mm, 0.25 mm, or 0.1 mm or any distance within this range.
- the present disclosure relates to a method for contacting blood with ozone ( FIG. 3 ).
- the method comprises receiving a flow of blood 301 into an ozonation system.
- the method may include injecting microbubbles of ozone containing gas 303 into the flow of blood.
- the method may include delivering the ozonated blood from the system 305 .
- the blood is at a temperature of less than 12° C. during the injecting of ozone.
- Ozone containing gas is preferably provided as microbubbles that have a mean diameter of less than 5 ⁇ m.
- the temperature of the blood during ozone injection is preferably between about 4° C. and about 10° C., such as 5° C., 6° C., 7° C., 8° C., or 9° C.
- the ozone containing gas is normally produced by an ozone generator that produces a mixture of ozone and oxygen comprising between 5% and 20% ozone, a range and ratio as described above.
- the concentration of ozone in the ozone containing gas injected into the flow of blood is preferably less than 10 grams/m 3 and more preferably less than 5 grams/m 3 .
- the concentration of ozone in the ozone containing gas is at least 1 gram/m 3 .
- the pressure of gas being injected may be for example, at least 0.1 bar and preferably up to 0.5 bar, 0.75 bar or 1.0.
- the ratio of the volumetric flow rate of blood and the volumetric flow rate of ozone containing gas may be adjusted to be in a range of from about 10:1 to about 50:1.
- the volumetric flow rate of blood may be in the range of from 0.1 Liters/hour to 12 Liters/hour, for example 3 Liters/hour to 6 Liters/hour.
- the delivered dose of ozone in the blood flow is less than 10 ppm, and may be for example, 1 ppm, 2 ppm, 3 ppm, 4 ppm, 5 ppm, 6 ppm, 7 ppm, 8 ppm, or 9 ppm.
- the flow of blood is preferably a laminar flow to minimize turbulence.
- the flow rates and pressures are controlled or set such that the microbubbles have a substantially uniform mean diameter of less than 5 ⁇ m in diameter.
- the flow rates and pressures are controlled or set such that the microbubbles completely dissolve in the flow of blood in less than 10 seconds, preferably less than 5 seconds, and more preferably less than 2 seconds.
- Controlling the flow and pressure of the ozone containing gas and blood flow rate in this way can prevent the microbubbles from coalescing into larger bubbles so that essentially all of the microbubbles entrained in the blood flow have the desired diameter.
- the method may further comprise cooling the blood 302 before ozone is injected into the flow of blood 303 .
- the blood may be warmed 304 before being delivered from the system 305 .
- the ozonated blood is to be stored, warming the blood may not be necessary, or alternatively cooling is provided as describe above.
- the flow of blood received into the ozonation system may optionally be pre-treated 301 a, for instance by a blood processing unit upstream the ozonation location.
- a blood processing unit upstream the ozonation location.
- an anticoagulant or other drug may be added to the blood flow.
- addition of such substance may be provided to ozonated blood, i.e. downstream the ozonation location.
- Extracorporeal treatment of blood introduces a possible undesired blood tampering, such as bubble formation, blood foaming, and the formation of clots or precipitates.
- the method may therefore include one or more post treatment processing steps 304 a to remove foam, bubbles, clots, and/or precipitates, as described above.
- Blood ozone contacting time and temperature may be optimized for killing particular microorganisms, or microbes.
- the contacting may be comprise the administration of drugs that may have an additive or synergistic effect with the ozone to kill microbes and/or a protective effect to reduce unwanted or adverse effects associated with contacting blood with an ozone containing gas.
Abstract
An apparatus, system, and method for contacting blood with ozone to kill microorganisms in the blood are described. The method involves injecting microbubbles of ozone containing gas into a flow of blood, preferably at a temperature of less than 12° C. The apparatus includes a blood flow conduit including a blood ozone contacting portion including a porous ozone injector.
Description
- This application is a continuation of and claims priority to U.S. patent application Ser. No. 16/815,997 filed Mar. 11, 2020, entitled Apparatus And Method For Contacting Blood With Ozone, which is a continuation of and claims priority to U.S. patent application Ser. No. 15/511,194 filed Mar. 14, 2017 entitled Apparatus And Method For Contacting Blood With Ozone, which is the U.S. National Phase of and claims priority to International Patent Application No. PCT/SE2015/050964, International Filing Date Sep. 15, 2015, entitled Apparatus And Method For Contacting Blood With Ozone; which claims benefit of the Swedish Patent Application Serial No. 1451072-1, filed Sep. 15, 2014 entitled Apparatus And Method For Contacting Blood With Ozone, all of which are hereby incorporated by reference in their entireties.
- The present invention relates to methods and apparatus for treating biological fluids with ozone. More particularly, the invention pertains to methods and apparatus for treating blood with ozone.
- Ozone is a strong oxidizing agent that has been used as a disinfectant. Despite the corrosive and highly reactive nature of ozone, the use of ozone to kill or inactivate certain infectious agents in blood has been explored. For example, US 2005/0189302 A1 discloses a method of inactivating viruses in blood by exposing the blood to ozone in a gas-fluid contacting device that maximizes gas-fluid mass transfer. The contacting device contains spheres or rods to form a thin film of blood and treatment is preferably performed at ambient temperature. WO 2011/162805 A2 discloses methods for inactivating infectious prion proteins in blood by subjecting blood to an ozone/oxygen admixture using a gas-fluid contacting device similar to that disclosed in US 2005/0189302 A1.
- WO 93/15779 A1 discloses a method of increasing the nitric oxide concentration in the blood by contacting a sample of blood with ozone gas and ultraviolet radiation. The treated sample of blood is administered to a patient to treat a variety of conditions including bacterial, fungal, viral, and protozoal infection. The blood sample is most preferably a volume of 1 to 50 mL and is most preferably treated at a temperature of 42.5° C. for approximately 3 minutes.
- U.S. Pat. No. 6,027,688 discloses a method for inactivating viruses, bacteria, fungi and protozoa in blood by contacting a flow of blood with counter-flow of an ozone-oxygen mixture for about 16 seconds using a gas-liquid contact apparatus.
- Treating milk and other liquid foodstuffs with ozone to kill bacteria is known. WO 2008/066470 discloses a method for inhibiting bacterial growth in milk by exposing the milk to a finely divided gas stream containing ozone at ambient temperature. The method of ozonation disclosed in WO2008/066470 can be improved regarding efficiency. Also, the temperature of the liquid ozonized is ambient temperature. The ambient temperature may be an ambient storage and transport temperature, but the temperature at the ozonation location is not disclosed as needing temperature control in the method disclosed in WO2008/066470.
- Although ozone has been used for killing microbes in large volumes of dairy products, such methods would destroy blood cells and inactivate enzymes and other proteins in the blood.
- There is a need for methods and apparatus to treat and prevent serious bacterial, fungal, and viral infections that are not susceptible to treatment by conventional means such as antibiotic, antifungal, and antiviral drugs. Although ozone is known to kill microbes in blood, previously described methods do not provide adequate microbe killing without damaging the blood. Thus, there is a need for apparatus and methods for ozonating blood in a way that kills microbes in the blood of a patient without damaging blood cells or interfering with the normal function of blood in the patient. Related apparatus and method may also be used to ozonate blood before and/or after storage to kill microbes in the blood before storage and/or administration to a patient. Human and nonhuman animal patients suffering, for example, from microbial infection in the blood would benefit from such apparatus and methods, particularly in cases where convention drug therapy is not effective. Hence, an improved system, apparatus, and method for contacting blood with ozone would be advantageous.
- Embodiments of the present invention preferably seek to mitigate, alleviate or eliminate one or more deficiencies, disadvantages or issues in the art, such as the above-identified, singly or in any combination by providing an apparatus for contacting blood with ozone, an ozonation system comprising the apparatus, and a method for contacting blood with ozone, according to the appended patent claims. While the invention is described with respect to the ozonation of blood and contacting blood with ozone, the invention is applicable to the ozonation of other biological fluids such as blood plasma, blood cell suspensions, and suspensions of other cell types.
- The invention is disclosed in the appended independent patent claims. Some particular embodiments of the invention are defined in the appended dependent claims.
- According to one aspect of the disclosure, an ozonation apparatus for contacting blood with ozone is provided. The apparatus comprises an ozone injector adapted to inject microbubbles of ozone containing gas into a flow of blood in an ozonation zone of an ozone contacting chamber, or ozonation chamber. The apparatus may optionally comprise means for cooling blood entering the ozonation chamber and/or means for warming blood exiting the ozonation chamber.
- According to a further aspect of the disclosure, an apparatus for contacting blood with ozone gas is provided. The apparatus has an ozonation chamber, a blood flow inlet, and a blood flow outlet. The ozonation chamber includes an ozone injector 3 configured for connection to a source of ozone containing gas and to inject bubbles of ozone containing gas into a flow of blood through the ozonation chamber. The flow of blood is directed vertically upwards through the blood ozonation chamber during injection. Suitable conduits are provided for directing the flow in relation to gravity so that the flow is vertically upwards at injection of ozone into the blood. The ozonation chamber and the ozone injector are configured such that the vertically upwards flow of blood through the blood ozonation chamber entrains bubbles of ozone containing gas into said flow of blood for said ozonation. The gas bubbles become dissolved in the blood when entrained therein.
- According to another aspect of the disclosure, a blood ozonation system is provided. The system comprises the ozonation apparatus, a source of ozone connected to the ozone injector, conduits for receiving blood into and delivering blood from the apparatus, and pumping means for pumping blood through the system. The system optionally comprises cooling means for cooling the blood before entering the ozonation apparatus and/or warming means for warming ozonated blood leaving the ozonation apparatus.
- According to yet another aspect of the disclosure, a method for contacting blood with ozone is provided. The method involves contacting blood with micro-sized bubbles of a gas containing ozone. The blood is at a temperature of less than 12° C. when contacted with the microbubbles, the microbubbles have a mean diameter of less than 5 μm.
- According to yet another aspect of the disclosure, a method for contacting blood with ozone is provided. The method involves receiving blood, cooling the blood to a temperature of less than 12° C., contacting the chilled blood with microbubbles of a gas containing ozone, optionally warming the blood to a warmed temperature, and delivering the blood to a storage container or storage vessel.
- According to yet another aspect of the disclosure, a method for treating a patient suffering from microbial infection is provided. The method involves receiving blood from the patient, cooling the blood to a temperature of less than 12° C., contacting the chilled blood with microbubbles of a gas containing ozone, warming the blood, and returning the blood to the patient. The method is advantageously performed using the system or apparatus of the disclosure.
- Features for the second and subsequent aspects of the disclosure are as for the first aspect mutatis mutandis.
- Unless otherwise defined, all terms used herein, including technical and scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.
- The term “microorganism” as used herein is synonymous with “microbe” and means any microorganism including bacteria, virus, fungi or yeast, and including spores or dormant forms of such a microorganisms.
- These and other aspects, features and advantages of which embodiments of the invention are capable of will be apparent and elucidated from the following description of embodiments of the present invention, reference being made to the accompanying drawings, in which
-
FIG. 1 is a schematic of a first embodiment of an ozonation system comprising an apparatus for contacting blood with ozone. -
FIG. 2 is a schematic of a second embodiment of an ozonation system comprising an apparatus for contacting blood with ozone. -
FIG. 3 is a flow chart of method steps for a method for contacting blood with ozone. - Specific embodiments of the invention will now be described with reference to the accompanying drawings. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. The terminology used in the detailed description of the embodiments illustrated in the accompanying drawings is not intended to be limiting of the invention. In the drawings, like numbers refer to like elements.
- A first embodiment of an ozonation system according to the invention is shown in
FIG. 1 . The apparatus comprises an ozonation apparatus 1 comprising anozonation chamber 2 comprising an inlet 2 a and anoutlet 2 b, and an ozone injector 3. The ozone injector 3 is configured to be connected to a source of ozone gas 4. - The source of ozone gas may be an ozone generator that produces ozone from oxygen that may produce a gas mixture that contains ozone and oxygen at a certain ratio. Alternative gaseous ozone sources may be provided as known to the skilled person.
- The ratio of ozone to oxygen in the gas mixture may for example range from 5% to 20% ozone and from 95% to 80% oxygen. Preferable values of an ozone to oxygen ratios are 5/95, 10/90, 15/85 and 20/80.
- The ozone injector may be made from porous material, for example, from sintered stainless steel. Alternatively or in addition, it may be made from sintered ceramic. Alternatively, or in addition other gas injectors may be provided to provide ozone gas to enrich a flow of blood to be ozonized. Other gas injectors may be nozzle based. The porous material has in examples a uniform mean pore size of less than 5 μm in diameter, such as 4 μm, 3 μm, 2 μm, 1 μm, 0.5 μm, or 0.2 μm. The pore size is preferably between about 0.2 μm and about 2.0 μm.
- The ozone gas injector 3 may further comprises a flow meter, pressure valve, pressure sensor, and/or controlling element to facilitate monitoring and/or control the pressure and/or flow rate of gas being injected.
- The embodiment shown in
FIG. 1 shows an ozonation apparatus 1 comprising a porous ozone injector 3 inside anozonation chamber 2. The ozone injector is cylindrical in the example. The ozonation chamber is configured to guide a flow of blood around the porous microbubble releasing surface of the ozone injector 3. In the example, the ozone injector is cylindrical. Preferably, the cylindrical ozone injector 3 is arranged co-axially in the cylindrical ozonation chamber for advantageous ozonation efficiency. A gap exists between the inner wall of theozonation chamber 2 and the porous bubble releasing surface of the ozone injector 3. The bubble as preferably microbubbles as elucidated herein. - The flow of blood over the microbubble releasing surface is preferably a laminar flow to minimize turbulence in the blood flow.
- The blood flow is preferably directed vertically upwards so that gas bubbles entrain in the flow of blood. By directing the flow of gas in a vertical direction, gas bubbles are entrained upwardly. The gas bubbles are also provided to the entire flow of blood, independent of gravity. The gas bubbles are for instance evenly provided around a cylindrical ozone injector. In this manner, portions of blood that are not enriched with gas comprising ozone are avoided. The vertical direction provides thus advantageous (short) time of gas comprising ozone with the flow of blood until the gas is dissolved in the blood. This is important as for instance remaining gas bubbles returned to a patient have to avoided. In addition, foaming of the blood flow is advantageously reduced or avoided by the vertical arrangement of the blood flow.
- Compare e.g. horizontal arrangements as described in WO2008/066470, where portions liquid flow below an injector are not well or not at all ozonized as the bubbles raise upwardly along the injector, i.e. the flow portion above the injector is better ozonized than that below.
- The shape of the ozone injector 3 need not be cylindrical and not all surfaces of the ozone injector need to be in contact with blood. One alternative configuration is shown in
FIG. 2 . - The ozone injector 3 is arranged in the
ozonation chamber 2 such that blood flow is restricted to pass throughozonation chamber 2 within a maximum distance (d) of a porous surface of the ozone injector 3 from which microbubbles are released. The maximum distance (d) is preferably less than about 2 mm, such as 1.5 mm, 1.0 mm, 0.75 mm, 0.5 mm, 0.25 mm, or 0.1 mm or any distance within this range. - The
ozonation chamber 2 and ozone injector 3 are designed to provide anozonation zone 5 in which micrometer sized bubbles of ozone containing gas mix with and dissolve in a flow of blood. - When blood and ozone containing gas are flowing through the ozonation chamber 1, an
ozonation region 5, indicated as the region between the horizontal dashed lines inFIG. 1 , exists in which microbubbles are entrained in the blood flow. The bubbles are dissolved in the blood along the entrainment path in the blood flow. - The duration of ozone contacting time, or dwell time, is determined by a number of factors. These factors include the concentration of ozone in the gas, and the flow rate of the gas. Another factor is the temperature of the blood. The temperature at ozonation is preferably controlled in examples of the disclosure. Moreover, the flow rate of the blood is such a factor. Any or all of these factors may be measured, supervised, or controlled to optimize ozonation. The factors maybe computer controlled by controlling gas pressure and flow from the source of ozone 4. Alternatively, or in addition, the operation of blood pumping means 10 may be controlled. Optionally blood cooling means 11 are controlled for advantageous blood ozonation.
- A system according to an example of the present disclosure may comprise more than one ozonation apparatus. For example, a plurality of ozone apparatus may be arranged in parallel with respect to the flow of blood.
- Alternatively, or in addition, a single ozone apparatus can comprise a plurality of ozone injectors. Each or some of the plurality of ozone injectors may be arranged such that all blood moving through the ozonation chamber passes within the maximum distance (d) of at least one of the ozone injectors.
- The ozonation system shown in
FIG. 1 additionally may, as illustrated, comprises blood pumping means 10. The blood pumping means 10 are arranged for pumping blood through the apparatus or system from a blood inlet portion 8 to ablood outlet portion 9. Suitable blood pumping means 10 for pumping blood are known in the art and may comprise, for example, a peristaltic pump, a roller pump, or a centrifugal pump. Pumping means 10 may be capable of pumping blood through the system at a suitable flow rate. Suitable flow rates range for example from about 0.1 Liters/hour to about 12 Liters/hour. - The system may also comprise an ozone source 4, such as a medical grade ozone generator. The ozone generator is fluidly connected to the ozone injector 3 by a gas conduit 6. The gas conduit 6 may comprise a one-
way valve 7 to prevent backflow of blood into the ozone generator 6. Such backflow may occur in case of, for example, a sudden pressure drop in the gas conduit 6. - The ozone source 4 is preferably capable of delivering ozone at a constant pressure. The ozone source 4 is preferably capable of delivering at least 10% ozone at such a constant pressure. The constant pressure of gas is at least 0.1 bar and preferably up to 0.5 bar, 0.75 bar or 1.0 bar at the ozone injector 3.
- The system may additionally comprise a source of one or more inert gasses that may be mixed with the ozone containing gas before reaching the ozone injector. Examples of inert gasses include nitrogen and helium.
- The blood contacting portions of the system may preferably be made of any suitable biocompatible materials. Such materials include materials typically used to transfer or store blood, such as those used in tubing for transfusions or blood conducting portions of heart and lung machine or apheresis machines.
- The
blood entry portion 2 may comprise or be connectable to means for receiving blood from a patient such as a hollow needle for insertion in to a vein. - Alternatively or additionally,
blood entry portion 2 may comprise means for receiving blood from a container of blood. Such container may include a bag or bottle or an extracorporeal blood circulation device such as an apheresis machine, dialysis machine, or heart and lunch machine. - The ozonation system may comprise blood cooling means 11 positioned upstream of ozonation apparatus inlet 2 a and configured to cool the blood to a chilled temperature of less than 12° C. before the blood enters the ozonation apparatus 1.
- The blood cooling means 11 may comprise any suitable blood heat exchanger used in the medical arts to cool blood and may be configured for computer control of the temperature of the blood entering the
ozonation chamber 2. - The blood cooling means 11 is preferably controllable to cool said blood to a temperature of between about 4° C. and about 12° C., to produce chilled blood that is contacted with ozone containing gas in the
ozonation chamber 2. - It is understood that cooling is a relative term. If for instance blood entering into the ozonation system has a temperature lower than desired, e.g. lower than between about 4° C. and about 12° C., it maybe provided to actually heat the blood to this preferred temperature range. This may be the case for frozen blood preservatives, e.g. frozen blood plasma. Cooling can be understood a term relative to ambient room temperature. Cooling is also relative physiological body temperature if blood is input to the ozonation system at body temperature from a patient.
- At ozonation in the ozonation chamber, the blood thus has preferably a temperature of less than 12° C. It preferably has a temperature between about 4° C. and about 12° C. The chilled blood is then contacted at this temperature with ozone containing gas in the
ozonation chamber 2. - Additionally or alternatively, the ozonation system may comprise blood warming means 12. The blood warming means is preferably positioned downstream the ozonation chamber. The blood warming means is for example positioned downstream of the
outlet 2 b from the ozonation apparatus 1. The blood warming means is configured to warm ozonated blood to a temperature above the blood temperature in theozonation chamber 2. - The blood warming means 12 may be configured to warm blood to a body temperature of a human or nonhuman animal, e.g. between about 24° C. to about 39° C.
- Blood warming means 12 may additionally or alternatively be configured to adjust the temperature of the blood to a storage temperature. It is understood that warming is a relative term. If for instance blood leaving the ozonation system has a temperature higher than desired to exit the apparatus or system, it maybe provided to actually, potentially further, cool the blood to this desired temperature. This may be the case when it is desired to provide ozonated frozen blood preservatives, e.g. frozen blood plasma, with advantageous storage properties compared to not ozonated blood products.
- Blood warming will in most examples include feeding heat energy to the ozonated blood to increase the temperature thereof.
- Blood warming means 12 may be computer controlled similarly to blood cooling means 11.
- The system may comprise a
blood processing unit 13 comprising means for removing bubbles, preferably downstream the ozone injector. Alternatively, or in addition, the system may comprise ablood processing unit 13 comprising means for removing foam, preferably downstream the ozone injector. Alternatively, or in addition, the system may comprise ablood processing unit 13 comprising means for removing thrombi, preferably downstream the ozone injector. In this manner, undesired bubbles, foam, thrombi, and/or other material may be suitably removed. The treatment may be at least partially be done upstream the ozonation chamber. The treatment is preferably done downstream (relative blood flow) the ozonation chamber, for instance before the blood can be delivered to a patient or to a blood storage container. -
Blood processing unit 13 may comprise, for example, a filter for removing particles . Alternatively, or in addition, theblood processing unit 13 may comprise a blood reservoir comprising an inlet region separated from an outlet region by a membrane that is permeable for blood, but impermeable for air bubbles. - A
blood processing unit 13 downstream the ozonation chamber may be particularly useful in embodiments of the invention used to ozonate blood that is to be delivered to a patient. - All or parts of the apparatus and/or system may be combined with and/or controlled by a
computerized control system 19. Thecomputerized control system 19 may be electrically coupled to sensors, actuators, valves, and/or switches in the ozonation system. - The
control system 19 may comprise software having code segments configured to control operational parameters of the apparatus. Operational parameters include parameters such as blood and gas flow rates and pressures, the concentration of ozone and other gasses in the ozone containing gas, blood temperature in the different portions of the apparatus, and blood flow rates in various portions of the apparatus and/or system conduit based upon sensor data received from pressure, flow, temperature, and/or chemical sensors provided in various portions of the apparatus. -
FIG. 2 shows an example of an ozonation system comprising an alternatively configured ozonation apparatus 1. Only the top surface of the ozone injector 3 is in contact with blood and injects microbubbles of ozone containing gas into a flow of blood that entrains the injected microbubbles. Anozonation region 5 is located directly above the ozone injector 3 in which the microbubbles completely dissolve in the blood. - Without intending to be bound by theory, it is believed that the ozone is also entirely consumed by chemical reactions with the blood within the
ozonation region 5. - The
ozonation chamber 2 is configured such that all of the blood flow passes within a maximum distance (d) from the upper surface of the ozone injector 3. The maximum distance (d) is preferably less than about 2 mm, such as 1.5 mm, 1.0 mm, 0.75 mm, 0.5 mm, 0.25 mm, or 0.1 mm or any distance within this range. - Alternatively, the diameter of blood flow can be narrowed above the ozone injector 3 such that a flow of blood entrains a flow of microbubbles in an
ozonation zone 5 above the injector. - With such an embodiment, the maximum distance from the surface of the ozone injector 3 may be greater than in other embodiments. The diameter of the flow in the
ozonation zone 5 is preferably less than about 2 mm, such as 1.5 mm, 1.0 mm, 0.75 mm, 0.5 mm, 0.25 mm, or 0.1 mm or any distance within this range. - In one aspect, the present disclosure relates to a method for contacting blood with ozone (
FIG. 3 ). In a first example, the method comprises receiving a flow ofblood 301 into an ozonation system. The method may include injecting microbubbles ofozone containing gas 303 into the flow of blood. Further, the method may include delivering the ozonated blood from thesystem 305. Preferably, the blood is at a temperature of less than 12° C. during the injecting of ozone. Ozone containing gas is preferably provided as microbubbles that have a mean diameter of less than 5 μm. The temperature of the blood during ozone injection is preferably between about 4° C. and about 10° C., such as 5° C., 6° C., 7° C., 8° C., or 9° C. - The ozone containing gas is normally produced by an ozone generator that produces a mixture of ozone and oxygen comprising between 5% and 20% ozone, a range and ratio as described above.
- The concentration of ozone in the ozone containing gas injected into the flow of blood is preferably less than 10 grams/m3 and more preferably less than 5 grams/m3. Preferably, the concentration of ozone in the ozone containing gas is at least 1 gram/m3.
- The pressure of gas being injected may be for example, at least 0.1 bar and preferably up to 0.5 bar, 0.75 bar or 1.0.
- The ratio of the volumetric flow rate of blood and the volumetric flow rate of ozone containing gas may be adjusted to be in a range of from about 10:1 to about 50:1.
- The volumetric flow rate of blood may be in the range of from 0.1 Liters/hour to 12 Liters/hour, for example 3 Liters/hour to 6 Liters/hour.
- The delivered dose of ozone in the blood flow is less than 10 ppm, and may be for example, 1 ppm, 2 ppm, 3 ppm, 4 ppm, 5 ppm, 6 ppm, 7 ppm, 8 ppm, or 9 ppm.
- The flow of blood is preferably a laminar flow to minimize turbulence.
- The flow rates and pressures are controlled or set such that the microbubbles have a substantially uniform mean diameter of less than 5 μm in diameter.
- The flow rates and pressures are controlled or set such that the microbubbles completely dissolve in the flow of blood in less than 10 seconds, preferably less than 5 seconds, and more preferably less than 2 seconds.
- Controlling the flow and pressure of the ozone containing gas and blood flow rate in this way can prevent the microbubbles from coalescing into larger bubbles so that essentially all of the microbubbles entrained in the blood flow have the desired diameter.
- If the method is to be performed on blood from a patient or other source of blood that has a temperature higher than the ozonation temperature, the method may further comprise cooling the
blood 302 before ozone is injected into the flow ofblood 303. - If the blood is to be returned to a patient or stored at a temperature above the ozonation temperature, the blood may be warmed 304 before being delivered from the
system 305. - If the ozonated blood is to be stored, warming the blood may not be necessary, or alternatively cooling is provided as describe above.
- The flow of blood received into the ozonation system may optionally be pre-treated 301 a, for instance by a blood processing unit upstream the ozonation location. Alternatively or in addition, for example, an anticoagulant or other drug may be added to the blood flow. Alternatively, or in addition, addition of such substance may be provided to ozonated blood, i.e. downstream the ozonation location.
- Extracorporeal treatment of blood introduces a possible undesired blood tampering, such as bubble formation, blood foaming, and the formation of clots or precipitates. The method may therefore include one or more post treatment processing steps 304 a to remove foam, bubbles, clots, and/or precipitates, as described above.
- Blood ozone contacting time and temperature may be optimized for killing particular microorganisms, or microbes.
- The contacting may be comprise the administration of drugs that may have an additive or synergistic effect with the ozone to kill microbes and/or a protective effect to reduce unwanted or adverse effects associated with contacting blood with an ozone containing gas.
- The present invention has been described above with reference to specific embodiments. However, other embodiments than the above described are equally possible within the scope of the invention as defined in the appended patent claims.
Claims (20)
1. A method for contacting blood with ozone, the method comprising:
receiving a flow of blood into an ozonation apparatus;
injecting bubbles of an ozone containing gas into the flow of blood; and
delivering the flow of blood that is ozonated from the ozonation apparatus;
wherein the flow of blood is vertically upwards during the injecting of bubbles of the ozone containing gas.
2. The method of claim 1 , further comprising cooling the flow of blood to a temperature of less than 12° C. before the receiving of the blood flow.
3. The method of claim 1 , further comprising cooling the blood in the flow of blood upstream of a location of the injection of ozone to a temperature of less than 12° C. during the injecting of ozone.
4. The method of claim 1 , further comprising warming the ozonated blood in a blood flow exiting the apparatus upstream of a location of the injection of ozone.
5. The method of claim 1 , wherein injecting the bubbles further comprises injecting microbubbles that have a mean diameter of less than 5 μm.
6. The method of claim 1 , wherein the ozone containing gas comprises less than 10 grams of ozone per cubic meter or wherein the ozone containing gas comprises 5% to 20% ozone by weight and 95% to 80% oxygen by weight.
7. The method of claim 1 , wherein the flow of blood during the injecting is from about 0.1 Liters/hour to about 10 Liters/hour and a flow rate of the ozone containing gas is about 0.01 Liters per hour to about 1 Liter per hour.
8. The method of claim 1 , further comprising dissolving the bubbles completely in the flow of blood less than 10 seconds after the injecting for the ozonation of the blood.
9. The method of claim 1 , further comprising injecting the ozone containing gas into the flow of blood at a pressure of less than 1 bar.
10. The method of claim 1 , further comprising adjusting 1) a flow rate of the blood, 2) an injection pressure of ozone containing gas, and/or 3) a flow rate of ozone containing gas; and preventing or minimizing a coalescence of bubbles during the injecting bubbles of the ozone containing gas by the adjusting.
11. The method of claim 1 , further comprising performing in vitro ozonation of the blood.
12. The method of claim 11 , wherein the in-vitro ozonation of the blood is made prior to storage of the blood and providing enhanced storage time of the ozonated blood compared to the blood when not ozonated.
13. The method of claim 11 , wherein the in-vitro ozonation of the blood is made after storage of the blood and/or before administration of the blood to a patient.
14. The method of claim 1 , further comprising performing in vivo ozonation of the blood.
15. The method of claim 14 , further comprising performing therapeutic or preventive treatment of a patient.
16. The method of claim 14 , further comprising extracting blood from a patient, ozonating the blood, and feeding back the ozonated blood to the patient.
17. The method of claim 14 , further comprising performing dialysis treatment of the flow of blood of a patient.
18. The method of claim 14 , further comprising ozonation of the blood in a flow of blood in an apheresis machine, dialysis machine, or heart and lunch machine.
19. A method for contacting blood with ozone, the method comprising:
receiving a flow of blood into an ozonation apparatus;
reducing or avoiding foaming of the flow of blood by injecting bubbles of an ozone containing gas into the flow of blood such that the ozone containing gas entrains and dissolves within the flow of blood; and
delivering the flow of blood that is ozonated from the ozonation apparatus.
20. A method for contacting blood with ozone, the method comprising:
receiving a flow of blood into an ozonation apparatus;
directing the flow of blood vertically upwards;
injecting bubbles of an ozone containing gas into the flow of blood directed vertically upwards; and
delivering the flow of blood that is ozonated from the ozonation apparatus.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/815,549 US20220362451A1 (en) | 2014-09-15 | 2022-07-27 | Apparatus And Method For Contacting Blood With Ozone |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1451072A SE541036C2 (en) | 2014-09-15 | 2014-09-15 | Apparatus and system for ozonating blood, and method for ozonating blood prior to storage |
SE1451072-1 | 2014-09-15 | ||
PCT/SE2015/050964 WO2016043649A1 (en) | 2014-09-15 | 2015-09-15 | Apparatus and method for contacting blood with ozone |
US201715511194A | 2017-03-14 | 2017-03-14 | |
US16/815,997 US11426505B2 (en) | 2014-09-15 | 2020-03-11 | Apparatus and method for contacting blood with ozone |
US17/815,549 US20220362451A1 (en) | 2014-09-15 | 2022-07-27 | Apparatus And Method For Contacting Blood With Ozone |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/815,997 Continuation US11426505B2 (en) | 2014-09-15 | 2020-03-11 | Apparatus and method for contacting blood with ozone |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220362451A1 true US20220362451A1 (en) | 2022-11-17 |
Family
ID=55533566
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/511,194 Abandoned US20170274133A1 (en) | 2014-09-15 | 2015-09-15 | Apparatus and method for contacting blood with ozone |
US16/815,997 Active 2035-09-26 US11426505B2 (en) | 2014-09-15 | 2020-03-11 | Apparatus and method for contacting blood with ozone |
US17/815,549 Pending US20220362451A1 (en) | 2014-09-15 | 2022-07-27 | Apparatus And Method For Contacting Blood With Ozone |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/511,194 Abandoned US20170274133A1 (en) | 2014-09-15 | 2015-09-15 | Apparatus and method for contacting blood with ozone |
US16/815,997 Active 2035-09-26 US11426505B2 (en) | 2014-09-15 | 2020-03-11 | Apparatus and method for contacting blood with ozone |
Country Status (7)
Country | Link |
---|---|
US (3) | US20170274133A1 (en) |
EP (1) | EP3193948A4 (en) |
JP (2) | JP6979357B2 (en) |
CN (2) | CN107073149A (en) |
CA (1) | CA2967307A1 (en) |
SE (1) | SE541036C2 (en) |
WO (1) | WO2016043649A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE541036C2 (en) * | 2014-09-15 | 2019-03-12 | Sangair Ab | Apparatus and system for ozonating blood, and method for ozonating blood prior to storage |
CN112370592B (en) * | 2020-10-09 | 2022-08-30 | 天津大学 | Medical ozone therapeutic instrument capable of automatically realizing ozone autohemotherapy |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3906034C1 (en) * | 1989-02-27 | 1990-09-27 | Dr. J. Haensler Gmbh, 7557 Iffezheim, De | |
EP1243278B1 (en) | 1992-02-07 | 2007-01-03 | Vasogen Ireland Limited | Use of blood having an increased concentration of nitric oxide for the manufacture of a medicament |
WO1994003217A1 (en) | 1992-07-31 | 1994-02-17 | Wainwright Basil E | Apparatus and method for inactivation of human immunodeficiency virus |
JP2868680B2 (en) * | 1992-11-30 | 1999-03-10 | 三星電子株式会社 | Data recording method for facsimile machine |
GB9424913D0 (en) * | 1994-12-09 | 1995-02-08 | Lifetech Corp | Enhancement of treatment processes |
GB9502347D0 (en) * | 1995-02-07 | 1995-03-29 | Ca Nat Research Council | Method and apparatus for inactivation of viruses in body fluids |
JPH08225095A (en) * | 1995-02-21 | 1996-09-03 | Yoji Kato | Microbubble generating device |
JPH08225094A (en) * | 1995-02-21 | 1996-09-03 | Yoji Kato | Microbubble generating device |
US5811014A (en) * | 1996-11-12 | 1998-09-22 | Sanitrol Systems, Inc. | Hazardous flowable waste sanitizing and remediating process and apparatus |
JPH11217856A (en) * | 1997-07-10 | 1999-08-10 | (有)レーベン | Washing method of feed water pipeline, ozone-containing bubble generator used therein, and adapter for injecting ozone-containing bubble |
IT1304503B1 (en) * | 1998-12-24 | 2001-03-19 | In Te C S R L | USE OF A SELECTIVE MEMBRANE IN A BIOMEDICAL DEVICE FOR THE EXTRA-BODY TREATMENT OF BLOOD AND OTHER ORGANIC LIQUIDS. |
US6251289B1 (en) * | 1999-06-03 | 2001-06-26 | Grt, Inc. | Treatment of contaminated liquids with oxidizing gases and liquids |
JP2001340847A (en) * | 2000-06-01 | 2001-12-11 | Canon Inc | Aeration/separation apparatus for removing/separating algae, green algae, and red tide plankton |
AU2002367942A1 (en) * | 2001-11-02 | 2003-12-22 | Medizone International, Inc. | Method and apparatus for ozone decontamination of biological liquids |
CA2481144A1 (en) | 2002-04-12 | 2003-10-23 | Throwleigh Technologies, L.L.C. | Methods and apparatus for decontaminating fluids |
JP2004057703A (en) * | 2002-07-31 | 2004-02-26 | L'air Liquide Sa Pour L'etude & L'exploitation Des Procedes Georges Claude | Waste liquid treatment device of hemodialysis unit |
AU2003291706A1 (en) * | 2002-11-04 | 2004-06-07 | Ashland Licensing And Intellectual Property Llc | Device and process for treating a liquid medium using ultrasound in preventing the growth of hyperproliferative or infected cells |
WO2005018715A1 (en) | 2003-07-31 | 2005-03-03 | Lipidviro Tech | Ozone delivery system including gas-fluid contacting devices and methods of use |
US20050189302A1 (en) | 2003-07-31 | 2005-09-01 | Latino Joseph S. | Viral inactivation using ozone |
CN1660452A (en) | 2004-02-27 | 2005-08-31 | 汤宏勇 | Disinfecting device for blood |
US20120228396A1 (en) * | 2004-05-25 | 2012-09-13 | Gregory Scott Osborn | System and Method for Optimizing the Dissolution of a Gas in a Liquid |
US7931816B2 (en) * | 2004-12-29 | 2011-04-26 | Acos Llc | Method, apparatus and systems for treating contaminants in a waste fluid |
CN2865701Y (en) * | 2005-09-04 | 2007-02-07 | 郭罕斌 | High-pressure ozone blood purifying device |
CN1939545A (en) * | 2005-09-30 | 2007-04-04 | 郭罕斌 | High-pressure ozone blood purifier and purification |
CA2542673A1 (en) * | 2006-04-10 | 2007-10-10 | Peter Klaptchuk | Method and apparatus for pathogenic and chemical reduction in fluid waste |
JP2007278003A (en) * | 2006-04-11 | 2007-10-25 | Kubota Corp | Method and device for purifying sewage force-feed pipeline system |
SE530656C2 (en) * | 2006-11-30 | 2008-07-29 | Land & Sjoe Food Technology Ab | Ozone treatment of liquid foods |
US8530368B2 (en) | 2008-08-19 | 2013-09-10 | Basf Corporation | Blended hydrous kaolin clay product |
US8246564B2 (en) * | 2008-12-04 | 2012-08-21 | Therox, Inc. | System for enriching a bodily fluid with a gas having automated priming capabilities |
WO2011162805A2 (en) | 2010-06-21 | 2011-12-29 | Acquisci, Inc. | Prion inactivation using ozone |
WO2013082717A1 (en) * | 2011-12-06 | 2013-06-13 | Bachellier Carl Roy | Improved impeller apparatus and dispersion method |
FR2998486B1 (en) * | 2012-11-28 | 2014-11-21 | Alfaa France | DEVICE FOR TREATING FLUID |
US20160008525A1 (en) * | 2014-07-11 | 2016-01-14 | Jerry C Elliot | Hyperoxygenation/Hyperthermia Treatment Apparatus |
SE541036C2 (en) | 2014-09-15 | 2019-03-12 | Sangair Ab | Apparatus and system for ozonating blood, and method for ozonating blood prior to storage |
-
2014
- 2014-09-15 SE SE1451072A patent/SE541036C2/en unknown
-
2015
- 2015-09-15 WO PCT/SE2015/050964 patent/WO2016043649A1/en active Application Filing
- 2015-09-15 EP EP15842571.0A patent/EP3193948A4/en active Pending
- 2015-09-15 CA CA2967307A patent/CA2967307A1/en active Pending
- 2015-09-15 CN CN201580049555.8A patent/CN107073149A/en active Pending
- 2015-09-15 US US15/511,194 patent/US20170274133A1/en not_active Abandoned
- 2015-09-15 CN CN202310239200.1A patent/CN116236636A/en active Pending
- 2015-09-15 JP JP2017534513A patent/JP6979357B2/en active Active
-
2020
- 2020-03-11 US US16/815,997 patent/US11426505B2/en active Active
-
2021
- 2021-07-28 JP JP2021122880A patent/JP7391067B2/en active Active
-
2022
- 2022-07-27 US US17/815,549 patent/US20220362451A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP6979357B2 (en) | 2021-12-15 |
US11426505B2 (en) | 2022-08-30 |
JP7391067B2 (en) | 2023-12-04 |
CN116236636A (en) | 2023-06-09 |
US20170274133A1 (en) | 2017-09-28 |
EP3193948A1 (en) | 2017-07-26 |
CA2967307A1 (en) | 2016-03-24 |
JP2017529237A (en) | 2017-10-05 |
EP3193948A4 (en) | 2018-06-20 |
SE1451072A1 (en) | 2016-03-16 |
JP2021176566A (en) | 2021-11-11 |
CN107073149A (en) | 2017-08-18 |
US20200276382A1 (en) | 2020-09-03 |
SE541036C2 (en) | 2019-03-12 |
WO2016043649A1 (en) | 2016-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220362451A1 (en) | Apparatus And Method For Contacting Blood With Ozone | |
US20030232114A1 (en) | Method for liquid enrichment with oxygen and applications of enriched liquids | |
US20060127271A1 (en) | Non-thermal disinfection of biological fluids using non-thermal plasma | |
EP2268251B1 (en) | Mobile apparatus for the dispersion and transdermal delivery of pharmaceutical, medical or purified carbon dioxide gas | |
US20080262413A1 (en) | Method For Supplying Oxygenated Water To Promote Internal Healing | |
US20040081580A1 (en) | Use of nitric oxide and a device in the therapeutic management of pathogens in mammals | |
WO2000038758A1 (en) | Use of a selective membrane in a biomedical device for the extracorporeal treatment of blood and other organic fluids | |
US20030118473A1 (en) | Method and apparatus for ozone decontamination of biological liquids | |
KR101919406B1 (en) | Health Care System Using Quantum Energy Generator built-in Oxidized Nitrogen Contained Vaporizing Apparatus | |
JP2017529237A5 (en) | ||
AU5855394A (en) | Low pressure gas enriching film contact apparatus | |
WO2021203199A1 (en) | Infusing dissolved oxygen into i.v. fluids to provide short term emergency oxygenation of venous blood for compromised or trauma patients | |
US20160008525A1 (en) | Hyperoxygenation/Hyperthermia Treatment Apparatus | |
CN215460746U (en) | Extracorporeal circulation treatment equipment | |
RU2758124C1 (en) | Device for intravenous infusions in ozone therapy | |
WO2004007066A1 (en) | Non-thermal disinfection of biological fluids using non-thermal plasma | |
US11331342B2 (en) | Treatment of infections and associated pathophysiological conditions | |
CN111760121A (en) | Disposable tri-oxygen gas injection therapeutic apparatus | |
JP3085300U (en) | Hemodiafiltration device that injects ozone into the human body | |
CN113350598A (en) | Extracorporeal circulation treatment apparatus | |
RU89821U1 (en) | SYSTEM FOR FLOW OZONING | |
CN101745159A (en) | Transfusion ozone treatment machine | |
WO2001089601A1 (en) | Method and apparatus for ozone decontamination of biological liquids | |
CN101721760A (en) | Transfusion ozone therapy apparatus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |